The determinants of tumour immunogenicity

Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.

[1]  M. Burnet.  IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS. , 1964, British medical bulletin.

[2]  G. Klein,et al.  Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Thomas.  On immunosurveillance in human cancer. , 1982, The Yale journal of biology and medicine.

[4]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[5]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[6]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[7]  H. Schreiber,et al.  Antigenic cancer cells that escape immune destruction are stimulated by host cells. , 1995, Cancer research.

[8]  D. Hanahan,et al.  Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. , 1998, Cancer research.

[9]  M Cohn,et al.  A minimal model for the self-nonself discrimination: a return to the basics. , 2000, Seminars in immunology.

[10]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[11]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[12]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[13]  T. Schumacher,et al.  T-cell-receptor gene therapy , 2002, Nature Reviews Immunology.

[14]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[15]  O. Jose.  Melvin Cohn The immune system : a weapon of mass destruction invented by evolution to even the odds during the war of the DNAs , 2002 .

[16]  J. Krauss.  A return to basics , 2002 .

[17]  J. Becker,et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.

[18]  Melvin Cohn,et al.  The immune system: a weapon of mass destruction invented by evolution to even the odds during the war of the DNAs , 2002, Immunological reviews.

[19]  M. Dewhirst,et al.  Synergy between tumor immunotherapy and antiangiogenic therapy. , 2003, Blood.

[20]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[21]  B. Brors,et al.  Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-specific Genes Colocalized in Chromosomal Clusters , 2004, The Journal of experimental medicine.

[22]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[23]  T. Blankenstein,et al.  A cancer immunosurveillance controversy , 2004, Nature Immunology.

[24]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[25]  C. Huber,et al.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Sandro Sorella,et al.  Recent progress with the , 2005 .

[27]  G. Willimsky,et al.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.

[28]  G. Willimsky,et al.  Tumor‐induced antibodies resemble the response to tissue damage , 2005, International journal of cancer.

[29]  L. Zitvogel,et al.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.

[30]  E. Jaffee,et al.  Immunotherapy for pancreatic cancer — science driving clinical progress , 2005, Nature Reviews Cancer.

[31]  C. Blank,et al.  Immune resistance orchestrated by the tumor microenvironment , 2006, Immunological reviews.

[32]  C. Klebanoff,et al.  CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.

[33]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[34]  Thierry Boon,et al.  Human T cell responses against melanoma. , 2006, Annual review of immunology.

[35]  Thomas Pradeu,et al.  On the definition of a criterion of immunogenicity , 2006, Proceedings of the National Academy of Sciences.

[36]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[37]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[38]  O. Lantz,et al.  CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.

[39]  Fabian Kiessling,et al.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction , 2008, Nature.

[40]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[41]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[42]  H. Stein,et al.  Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness , 2008, The Journal of experimental medicine.

[43]  R. Offringa.  Antigen choice in adoptive T-cell therapy of cancer. , 2009, Current opinion in immunology.

[44]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[45]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[46]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[47]  D. Busch,et al.  Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. , 2009, Blood.

[48]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[49]  L. Zitvogel,et al.  Chemotherapy and radiotherapy: cryptic anticancer vaccines. , 2010, Seminars in immunology.

[50]  F. Garrido,et al.  “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy , 2010, International journal of cancer.

[51]  P. Courtoy,et al.  A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. , 2010, Cancer research.

[52]  T. Blankenstein,et al.  Transgenic mice with a diverse human T cell antigen receptor repertoire , 2010, Nature Medicine.

[53]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[54]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[55]  M. Kloor,et al.  Immune evasion of microsatellite unstable colorectal cancers , 2010, International journal of cancer.

[56]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[57]  E. Gilboa,et al.  Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay , 2010, Nature.

[58]  J. McNamara,et al.  Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[59]  P. Coulie,et al.  Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. , 2011, Cancer research.

[60]  J. Neefjes,et al.  Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.

[61]  Jonathan W. Uhr,et al.  Controversies in clinical cancer dormancy , 2011, Proceedings of the National Academy of Sciences.

[62]  A. Maitra,et al.  Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer , 2011, PloS one.

[63]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[64]  M. Weller,et al.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor , 2011, Nature.

[65]  T. van Hall,et al.  Strategies to counteract MHC-I defects in tumors. , 2011, Current opinion in immunology.

[66]  G. Kroemer,et al.  Prognostic and predictive impact of intra- and peritumoral immune infiltrates. , 2011, Cancer research.

[67]  C. Uyttenhove,et al.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase , 2012, Proceedings of the National Academy of Sciences.

[68]  T. Blankenstein,et al.  B‐cells and IL‐4 promote methylcholanthrene‐induced carcinogenesis but there is no evidence for a role of T/NKT‐cells and their effector molecules (Fas‐ligand, TNF‐α, perforin) , 2012, International journal of cancer.

[69]  K. Rezvani,et al.  Vaccination Strategies in Lymphomas and Leukaemias , 2011, Drugs.

[70]  J. Delrow,et al.  Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State , 2012, Science.

[71]  C. Parker,et al.  Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer , 2012, Journal of the National Cancer Institute.